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Michael J Sweeting, Katya L Masconi, Edmund Jones, Pinar Ulug, Matthew J Glover, Jonathan A Michaels, Matthew J Bown, Janet T Powell, 
Simon G Thompson
Summary
Background A third of deaths in the UK from ruptured abdominal aortic aneurysm (AAA) are in women. In men, 
national screening programmes reduce deaths from AAA and are cost-effective. The benefits, harms, and cost-
effectiveness in offering a similar programme to women have not been formally assessed, and this was the aim of 
this study.
Methods We developed a decision model to assess predefined outcomes of death caused by AAA, life years, quality-
adjusted life years, costs, and the incremental cost-effectiveness ratio for a population of women invited to AAA 
screening versus a population who were not invited to screening. A discrete event simulation model was set up for 
AAA screening, surveillance, and intervention. Relevant women-specific parameters were obtained from sources 
including systematic literature reviews, national registry or administrative databases, major AAA surgery trials, and 
UK National Health Service reference costs.
Findings AAA screening for women, as currently offered to UK men (at age 65 years, with an AAA diagnosis at an 
aortic diameter of ≥3·0 cm, and elective repair considered at ≥5·5cm) gave, over 30 years, an estimated incremental 
cost-effectiveness ratio of £30 000 (95% CI 12 000–87 000) per quality-adjusted life year gained, with 3900 invitations 
to screening required to prevent one AAA-related death and an overdiagnosis rate of 33%. A modified option for 
women (screening at age 70 years, diagnosis at 2·5 cm and repair at 5·0 cm) was estimated to have an incremental 
cost-effectiveness ratio of £23 000 (9500–71 000) per quality-adjusted life year and 1800 invitations to screening 
required to prevent one AAA-death, but an overdiagnosis rate of 55%. There was considerable uncertainty in the cost-
effectiveness ratio, largely driven by uncertainty about AAA prevalence, the distribution of aortic sizes for women at 
different ages, and the effect of screening on quality of life.
Interpretation By UK standards, an AAA screening programme for women, designed to be similar to that used to 
screen men, is unlikely to be cost-effective. Further research on the aortic diameter distribution in women and 
potential quality of life decrements associated with screening are needed to assess the full benefits and harms of 
modified options.
Funding UK National Institute for Health Research Health Technology Assessment programme.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 licence.
Introduction
Abdominal aortic aneurysm (AAA) traditionally has 
been considered a disease of men, strongly associated 
with smoking. However, a third of deaths caused by 
AAA rupture are in women.1,2 In men, synthesis of four 
randomised trials has shown a benefit of population-
based screening in reducing AAA-related mortality by 
up to 40% although any reduction in all-cause mortality 
is small.3,4 Several countries including Sweden and the 
UK have introduced cost-effective population screening 
programmes for AAA in men aged at least 65 years, and 
screening for older men is available in the USA, and 
regionally in Italy and other countries.5–8 The only 
randomised trial of AAA screening in women, which 
was done in the 1990s, was underpowered.9 In 2014, 
the US Preventive Services Task Force recommended 
against screening in women.7 The reasons for this 
recommendation include the reportedly lower 
prevalence of AAA in women, on the basis of the 
maximum aortic diameter thresh old of at least 3 cm, 
and paucity of evidence about the management of 
AAA in women.10 However, with long-term health-
economic modelling in men suggesting that population-
based screening would be cost-effective with an AAA 
prevalence as low as 0·35–0·5%, smoking now almost 
as common in women as in men, and with the 
association between smoking and AAA almost twice as 
strong for women compared with men, the case for 
AAA screening in women needs to be formally 
assessed.11–13
There would be no quick answers from doing a 
randomised trial of AAA screening in women, because of 
the large sample size and long-term follow-up that would 
be required. The alternative is long-term modelling. 
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This requires contemporary and reliable estimates of 
parameters that can influence the clinical and cost-
effectiveness of screening in women. The aim of this 
project was to obtain this information and then apply 
discrete event simulation modelling to explore the 
hypothesis that a variation of the current AAA screening 
programmes for men might prove clinically beneficial 
and cost-effective in reducing deaths from ruptured AAA 
in women.
Methods
Study design and participants
A decision model was developed to assess the differences 
in life-years, quality-adjusted life-years (QALYs) and costs 
for a population of women invited to AAA screening 
versus a population who were not invited to screening 
(the status quo). The West of Scotland Research Ethics 
Committee (number 5) provided a favourable ethical 
opinion for the project (reference 15/WS/0136). A public 
focus group was convened to provide input to the project 
(appendix).
The reference case assessed the long-term cost-
effectiveness of an invitation to a single ultrasound 
screen for all women in the UK at age 65 years, based on 
the UK National Abdominal Aortic Aneurysm Screening 
Programme (NAAASP) for men; namely a diagnosis of 
AAA when aortic diameter was at least 3·0 cm, annual 
surveillance for individuals with the smallest AAA 
(3·0–4·4 cm) at their most recent scan, a surveillance 
scan every 3 months for those with a medium AAA 
Research in context
Evidence before this study
Historically, abdominal aortic aneurysm (AAA) has been 
considered to be a disease in older male smokers, with prevalence 
being 4–5 times higher in men than in women. We searched 
MEDLINE, Embase, and CENTRAL using the terms “abdominal 
aortic aneurysm”, “aneurysm”, “women” OR “gender” OR “sex” 
OR “women’s health” OR “sex difference”, “prevalence” OR 
“incidence” OR “occurrence” OR “frequency”, “screening”, and 
“population” OR “population-based”. The search was restricted to 
major European languages and the final search date was Jan 15, 
2017. Four randomised trials of population screening in older men 
have shown that screening can reduce AAA-related deaths by up 
to half, meta-analysis of these trials indicate a small decrease in 
all-cause mortality, and associated studies have shown that 
screening is cost-effective. Therefore, in many countries or 
regions, there are programmes for ultrasonographic AAA 
screening for men. In women, AAA screening is not 
recommended as there has been only a single underpowered 
randomised trial to date. However, the rupture rate of small AAAs 
is four times higher in women than in men, and a third of the 
deaths from AAA rupture are in women. Moreover, women with 
incidentally detected AAA are disadvantaged with respect to 
availability of elective repair, the types of treatment available, and 
the higher elective operative mortality and complication rates 
compared with men. Although the effect of AAA screening on 
quality of life has been assessed in men, the instruments used 
might not be sensitive to detect either small changes or changes 
in specific health domains such as depression and emotional 
status and, to our knowledge, there have been no studies in 
women to date.
Added value of this study
To our knowledge, this is the first study to formally assess the 
long-term benefits, costs, and harms of screening women aged 
65 years and older for AAA. Contemporary systematic reviews, 
original data, clinical trials, and registries were used to obtain 
woman-specific parameters to feed into a discrete event 
simulation model for AAA screening, surveillance and 
intervention. The model estimated the numbers of key 
screening and clinical events over time for 10 million women 
enrolled in a screening programme with a UK costs perspective. 
The flexibility of the model permitted assessment of the clinical 
and cost-effectiveness of screening women using the same 
protocol used for the nationwide UK AAA screening 
programme in men and a range of different scenarios that 
might be more suitable for women (eg, changing the age at 
screening, lowering the diagnosis threshold, or reducing the 
intervention threshold).
Implications of all the available evidence
Our findings suggest that a screening programme of women 
aged 65 years—using the same screening, surveillance, and 
intervention protocol as defined for men in the UK—would 
need 3900 women to be invited to screening to save one death 
from AAA; a third of the screening-detected AAAs would be 
overdiagnosed and such a programme would not be 
cost-effective in the UK. The best alternative screening scenario 
for women would be screening at age 70 years, diagnosis of 
AAA when the maximum aortic diameter reaches 2·5 cm, and 
with intervention considered when the AAA diameter reaches 
5·0 cm. In this scenario 1800 women would need to be invited 
to screening to save one death from AAA, but overdiagnosis 
would occur in more than half of screen-detected AAAs. 
By contrast, for AAA screening in men aged 65 years, recent 
estimates have shown that fewer than 700 men need to be 
screened to avoid one AAA-related death. There is considerable 
uncertainty as to whether this best alternative scenario in 
women would be cost-effective because of uncertainty in the 
key input parameter of AAA prevalence at different ages and a 
lack of information about the quality of life decrements 
associated with screening. Therefore, urgent research on the 
population-based aortic diameter distribution in older women, 
and on the quality of life decrements associated with screening, 
is necessary before closing the door on the possibility that in 
some health-care systems, population screening for AAA in 
women might be cost-effective.
See Online for appendix
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(4·5–5·4 cm), and referral to a vascular surgeon for a 
large AAA (5·5 cm).6 Those with no AAA detected would 
not be rescreened. We took a UK National Health Service 
(NHS) perspective for costs including invitation, 
screening, consultations, elective surgery, and emergency 
surgery for ruptured AAAs.14
A total of 12 different screening options were assessed, 
including changing the age at screening from 65 to 
70 years, lowering the diagnosis threshold from 3·0 cm 
to 2·5 cm (on the basis of available data on aortic 
diameter distribution in older women15), and reducing 
the intervention threshold from 5·5 cm to 5·0 cm or 
4·5 cm. The most cost-effective option was selected as 
the best alternative screening strategy.
Modelling
A discrete event simulation model was designed and 
implemented, as described in detail elsewhere.16 Briefly, a 
previous multi-state Markov model of AAA screening in 
men11 was redeveloped and programmed as a more 
flexible discrete event simulation model to allow rapid 
assessment of different screening options, and was 
validated for men against data from the randomised 
Multicentre Aneurysm Screening Study.16 The model 
simulated a sequence of key screening and clinical events 
for 10 million women (with results presented per 1 million 
women invited) from the time of invitation to screening 
up to their date of death or age 95 years (the time horizon). 
Each woman had a counterpart who shared some key 
characteristics (age, aortic diameter at baseline, rate of 
aortic growth, or potential time of non-AAA-related 
death), except that the counterpart was not invited to 
screening. The structure of the model (appendix) allowed 
women to drop out of the surveillance programme or for 
an AAA to be incidentally detected. Women who were 
referred for a consultation could either be returned to 
surveillance if their diameter, as confirmed by a CT scan, 
was less than the intervention threshold; placed on a 
waiting list for elective surgery; or not offered repair 
because of the high surgical risk associated with their 
comorbidities.17 Overdiagnosis and over-treatment rates 
were calculated by comparing those with screen-detected 
AAA with their unscreened counterpart. All analyses 
used R software for statistical computing (version 3.2.4).
Outcomes
Predefined outcomes from the model were death caused 
by AAA, life-years, QALYs, costs, and the incremental 
cost-effectiveness ratio (ICER). Both costs and life-years 
were discounted at 3·5% per annum (appendix). 
Secondary outcomes included the number of women 
who were overdiagnosed (screen-detected AAAs in which 
the disease would without screening have remained 
without symptoms or incidental detection), and the 
number of women who were over-treated (repairs of 
screen-detected AAA that would without screening not 
have resulted in AAA death or surgery).
Data sources 
Input parameters for women were obtained from a 
combination of literature reviews, clinical trial data, 
bespoke hospital datasets, and analysis of routine and 
registry data sources. Parameter values used in the 
reference case are described briefly here (for full details 
see appendix).
Prevalence of AAA at different ages, based on the 
standard definition of an aortic diameter of at least 3 cm 
was obtained from a systematic review of the literature,10 
and estimated as 0·43% (95% CI 0·23–0·80) and 
0·70% (0·37–1·34) for those aged 65 and 70 years 
respectively (the prevalence at age 70 being an 
interpolation between estimates at 65 and 75 years). The 
baseline aortic diameter distribution for women was 
obtained either from the screening of 70-year-old women 
in Sweden15 or using data from NAAASP6 re-weighted to 
give the appropriate prevalence for women (appendix). On 
the basis of the definition of the aortic diameter in AAAs 
being 50% larger than a normal aortic diameter,18 the 
former data suggested that 2·5 cm might be an appropriate 
alternative AAA threshold for women (appendix).
AAA growth rates were estimated from a previous 
study using linear mixed effects models,19 with 
1743 women providing 4800 person-years of observation 
for analysis (appendix). Rupture rates from the same 
study19 were modelled as a function of AAA diameter 
using joint longitudinal and time-to-event models, with 
rupture rates increasing with larger diameters (appendix).
Data on operative mortality for both endovascular 
(EVAR) and open aneurysm repairs, and elective and 
emergency operations were extracted from the UK 
National Vascular Registry20 and Hospital Episode 
Statistics (HES).21 The overall estimated 30-day mortality 
rates were 2·4% for elective EVAR, 8·1% for elective 
open repair, 35·9% for emergency EVAR and 44·2% for 
emergency open repair (appendix).
Attendance rates were obtained from the randomised 
AAA screening trial in women,9 72·7% at age 65 years, 
decreasing to 67·6% at age 70 years. More recent 
audit data from Leicester and London, UK, showed 
little evidence of differential loss to surveillance be-
tween women and men, or between self-referred and 
screen-detected individuals. Therefore, the loss to AAA 
sur veillance was assumed constant at 5·5 per 100 person-
years (based on unpublished NAAASP data for men 
[Jo Jacomelli, Public Health England, personal 
communication]). The incidental detection rate was 
calculated as 2·93 per 100 person-years derived from 
data reported from New Zealand (similar to unpublished 
UK data given in the appendix).22
Randomised trials of AAA screening have shown little 
evidence that an AAA screened-positive population has 
lower long-term health-related quality of life (HRQoL) 
than a population screened-negative or a population not 
invited to screening.23,24 For the reference case, QALYs 
for all women, screened and unscreened, were therefore 
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calculated using age and sex-specific UK population 
EuroQoL-5D utility survey data25 and any transient 
reduction in HRQoL following elective AAA repair was not 
considered. The HRQoL weights used were 0·78 for ages 
65–74 years, and 0·71 for ages of 75 years or older. In a 
sensitivity analysis, we investigated how possible HRQoL 
decrements resulting from diagnosis and surveillance, 
surgery (elective and emergency), and non-intervention for 
elective repair could affect mean QALYs and the cost-
effectiveness ratio.
Age-specific non-AAA mortality rates for women were 
estimated using two datasets: overall life tables from the 
UK population 2012–14 and rates of death by age and 
cause.26,27 Non-AAA mortality was calculated by subtracting 
AAA-specific death rates from overall mortality.
Costs were obtained from the NAAASP, 2014–15 NHS 
reference costs4 (pre-surgical consultation, post-surgical 
monitoring),14 and previous microeconomic modelling of 
the EVAR-1 (elective)28 and IMPROVE (emergency)29 
surgery trials. Key components of the trial-based elective 
and emergency repair costs (vascular ward and critical 
care hospital stay) were from contemporaneous women-
specific data from HES and updated 2014–2015 NHS 
reference costs. Other components were inflated to 
2014–15 prices to reflect general NHS inflation, by use of 
published indices.30 The costs of re-interventions were 
taken from published trial data,28 which were inflated by 
use of published indices.30
Parameter uncertainty
We did probabilistic sensitivity analyses to investigate the 
effect of parameter uncertainty on the cost-effectiveness 
results (for distributions of the input parameters see 
appendix). We also did a series of deterministic sensitivity 
analyses to investigate robustness of results to changes 
in individual or groups of parameters; key sensitivity 
analyses investigated varying the prevalence and using 
a re-weighted aortic diameter distribution from the 
Swedish screening study in women.15 Changes to the 
aortic diameter distribution used the same prevalence as 
in the reference case but included a higher proportion of 
women with more than 4·5 cm diameter AAA (17% of 
detected AAAs at screening compared with 0·8% in the 
reference case).
Role of the funding source
The National Institute of Health Research (NIHR) had 
no role in study design, data collection, data analysis, 
data interpre tation, in the writing of the report or in the 
decision to submit the article for publication. The views 
and opinions expressed herein are those of the authors 
and do not necessarily reflect those of the Health 
Technology Assessment (HTA) programme, NIHR, UK 
NHS, or Department of Health. The corresponding 
author had full access to all the data in the study and had 
final responsibility for the decision to submit for 
publication.
Reference case* Best alternative strategy†
Not invited to 
screening
Invited to screening Difference (% of that 
in non-invited group)
Not invited to 
screening
Invited to screening Difference (% of that in 
non-invited group)
Diagnosis and treatment
AAA detected 9529 11 697 2168 (23%) 13 835 22 924 9089 (66%)
Screen detected 0 3101 ·· 0 12 309 ··
Incidentally detected 9529 8596 ·· 13 835 10 615 ··
Elective AAA repair 2165 2618 452 (21%) 2375 3676 1301 (55%)
Elective AAA repair contraindicated 1173 1398 225 (19%) 1261 1956 695 (55%)
AAA rupture 9235 8839 –396 (–4%) 7465 6555 –910 (–12%)
Emergency AAA repair 2336 2239 –97 (–4%) 1869 1636 –233 (–13%)
AAA-related deaths 8388 8131 –257 (–3%) 6886 6321 –566 (–8%)
Elective surgery or long-term complications of elective 
repair
308 393 85 (28%) 324 547 223 (69%)
Rupture or long-term complications of emergency repair 8080 7738 –342 (–4%) 6562 5774 –789 (–12%)
Non AAA-related deaths 855 079 855 285 186 (<1%) 849 789 850 220 431 (<1%)
Re-intervention after elective repair 505 619 114 (23%) 543 913 370 (68%)
Re-intervention after emergency repair 322 302 –20 (–6%) 234 193 –41 (–18%)
Surveillance measurements 13 773 16 367 2594 (19%) 17 995 26 648 8653 (48%)
Overdiagnosis and overtreatment
Overdiagnosis of AAA‡ ·· 1036/3101 (33%) ·· ·· 6732/12 308 (55%) ··
Overtreatment of AAA§ ·· 94/752 (13%) ·· ·· 494/2077 (24%) ··
AAA=abdominal aortic aneurysm. *Invitation to screening at age 65 years, diagnosis threshold 3·0 cm, intervention threshold 5·5 cm. †Invitation to screening at age 70 years, diagnosis threshold 2·5 cm, 
intervention threshold 5·0 cm. ‡Screen-detected AAAs in which the disease would not have otherwise become evident (incidentally detected) or caused any problems (AAA rupture) within the woman’s 
lifetime. §Elective AAA repair arising from screen-detection of AAA that in the absence of screening would not have resulted in AAA death or surgery.
Table 1: Clinical benefits and harms of AAA screening in 1 million women from screening age until age 95 years
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Results
Using the same screening protocol as for 65-year-old men 
in NAAASP, screening detected AAA in 0·31% of the 
population resulting in 23% more AAAs detected in total 
from age 65 to 95 years, leading to an additional 
452 elective operations per 1 million women invited to 
screening, 21% more than predicted to occur under no 
screening (table 1). Most of these additional operations 
occurred between the ages of 67 and 77 years (figure 1A, 
appendix). By contrast, there were 97 (4%) of 2336 fewer 
emergency operations (appendix), and 396 (4%) of 9235 
fewer AAA ruptures, predominantly occurring after age 
70 years (figure 1A). Approximately half of the 
AAA ruptures in the group invited to screening occurred 
in women with aortic diameter of less than 3 cm at initial 
screening (appendix). There were 85 (7%) of 1269 fewer 
AAA-related deaths in the first 10 years after screening 
and 257 (3%) of 8388 fewer deaths overall from age 65 to 
95 years. For every four women who avoided an AAA-
death because of successful screening, one woman died 
due to additional elective repair (342 avoiding AAA-
related deaths because of screening vs 85 deaths caused 
by elective surgery after screening; table 1). There was an 
early negative effect of screening on deaths due to AAA 
because of the high operative mortality for elective repair, 
particularly since less than half of the repairs in women 
aged younger than 75 years used EVAR (figure 1B).20 
Overall, 3900 women would need to be invited to 
screening to prevent one AAA-related death.
For those invited to screening, the increase in mean 
QALYs was 0·0011 (SD 0·0008) and costs, which were 
discounted at 3·5% per year, increased by a mean of 
£34 (4·7), which gave an ICER of £30 000 (95% CI 
12 000–87 000) per QALY gained (table 2). The ICER fell 
considerably as the model time horizon increased because 
benefits from screening continued to accrue over a 30-year 
period (appendix). The wide confidence interval for the 
ICER was mainly due to uncertainty in the incremental 
QALYs (appendix). The probability that the reference case 
was cost-effective for different willingness-to-pay 
thresholds is shown in figure 2. Willingness-to-pay is the 
amount that a particular health provider is prepared to pay 
for each additional QALY of benefit, which for the National 
Institute of Health and Care Excellence is usually 
considered in the range of £20 000–30 000.
Doubling the AAA prevalence or changes to the aortic 
diameter distribution in the model both resulted in the 
ICER dropping below £20 000 per QALY gained (figure 3). 
Conversely, a halving of AAA prevalence or a doubling 
of the incidental detection and drop out rates from 
surveillance both resulted in a much larger ICER, whereas 
changes to other parameters were less influential. Possible 
reductions in HRQoL associated with an AAA diagnosis 
resulted in large changes in the ICER (a decrease in 
utility of 0·01, about 1·3% of the baseline value, during 
surveillance resulted in the ICER increasing to £43 000; 
appendix). Transient reductions in HRQoL following 
either elective or emergency surgery (affecting one in 
200 invited women) did not affect the ICER but sizeable 
lifetime reductions in HRQoL following non-intervention 
for repair (affecting one in 700 invited women) would 
have a larger effect. A combination of these effects resulted 
in the ICER increasing to £52 000 (figure 3).
A best alternative strategy was considered: offering 
screening at age 70 years, together with lowering the 
threshold for AAA diagnosis to 2·5 cm and lowering 
the threshold for considering surgery to 5·0 cm (table 1). 
This resulted in a substantially larger number of 
screen-detected AAAs (1·2% of the population) and 
Figure 1: Aneurysm deaths and aneurysm repairs for reference case and best 
alternative strategy
Data for reference case and best alternative strategy are shown. Reference case: 
invitation to screening at age 65 years, diagnosis threshold 3·0 cm; intervention 
threshold 5·5 cm. Best alternative strategy: invitation to screening at age 
70 years, diagnosis threshold 2·5 cm, intervention threshold 5·0 cm. Differences 
in elective operations, emergency operations and AAA deaths in 1 million 
women (invited to screening minus not invited to screening group; A). 
Percentage reduction in number of AAA deaths from screening by age (B). 
Because of small number volatility, the percent reduction in AAA deaths is not 
shown when the number of AAA deaths is less than 50 (approximately the 
first year after invitation to screening). AAA=abdominal aortic aneurysm.
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more elective repairs were done because of the 
screening programme (1301 more elective repairs in the 
best alternative strategy vs 452 more elective repairs in 
the reference case per 1 million invited women; figure 1A, 
appendix), attributable to the higher age and lowered 
intervention threshold. There was a greater overall 
reduction in emergency operations (appendix) and AAA-
related deaths (figure 1A), with 229 (12%) of 1914 fewer 
AAA-related deaths from age 70 to 80 years and 566 (8%) 
of 6886 fewer deaths overall from age 70 to 95 years, 
per 1 million women (figure 1B). However, there was 
also an increase in the number of AAA-deaths after 
elective repair: for every seven women who avoided an 
AAA-related death because of successful screening, 
two women died due to elective repair of screen-detected 
AAA (789 avoiding AAA-related deaths because of 
screening vs 223 deaths caused by elective surgery after 
screening; table 1). About a quarter of AAA ruptures 
in the group of women invited to screening occurred 
in those who initially had aortic diameter of less than 
2·5 cm (appendix). Overall, 1800 women would need to 
be invited to screening to prevent one AAA-related death.
The best alternative strategy gave an overall ICER of 
£23 000 (95% CI 9500–71 000; table 2). Across the 
probability sensitivity analyses there was a wide spread 
in the estimated incremental QALYs highlighting un-
certainty in parameters that affect differences in 
average life-expectancy between populations invited and 
not invited to screening, with narrower spread for 
incremental costs (appendix). The cost-effectiveness 
acceptability curve for this strategy was more favourable 
than the reference case (figure 2).
In the reference case, 33% of screen-detected AAAs 
would not otherwise have been identified during the 
woman’s lifetime (table 1). In the best alternative strategy, 
the rate of overdiagnosis increased to 55%. Of the 
752 screen-detected AAA elective repairs in the reference 
case and 2077 in the best alternative strategy per 1 million 
women, 94 (13%) and 494 (24%) were overtreated, 
respectively.
Discussion
Comprehensive modelling has shown that offering 
women screening for AAA, using the same screening 
protocol as for men in the UK, would reduce deaths from 
AAA in the UK by 7% in women aged from 65 to 75 years 
and by 3% in women aged from 65 to 95 years, would 
require 3900 screening invitations to avoid one AAA-death, 
and would be unlikely to be cost-effective. The best 
Reference case* Best alternative strategy†
Not invited to 
screening
Invited to 
screening
Difference Not invited to 
screening
Invited to 
screening
Difference
Life-years
Undiscounted 20·5451 20·5480 0·0029 16·4305 16·4353 0·0048
Discounted 13·9351 13·9367 0·0016 11·8599 11·8627 0·0028
Discounted, QA 10·4484 10·4495 0·0011 8·7257 8·7277 0·0020
Costs (£)
Undiscounted 90·33 126·23 35·90 84·53 134·93 50·40
Discounted 50·55 84·36 33·81 52·76 97·83 45·07
ICER (£ per life-year or QALY gained)
Discounted, life-years ·· ·· 21 620 (95% CI 8862–61 794) ·· ·· 16 016 (95% CI 6800–50 039)
Discounted, QA ·· ·· 30 170 (95% CI 12 238–87 002) ·· ·· 22 540 (95% CI 9522–70 638)
Selective sampling of individuals above the diagnosis threshold was used to calculate accurate incremental estimates whereas mean life-years and costs within groups were 
obtained from full population sampling. For consistency, estimates in the Invited group are therefore obtained by adding the incremental estimates to the estimates from 
the Not Invited group. QA=quality-adjusted. ICER=incremental cost-effectiveness ratio. QALY=quality-adjusted life-year. *Invitation to screening at age 65 years, diagnosis 
threshold 3·0 cm, intervention threshold 5·5 cm. †Invitation to screening at age 70 years, diagnosis threshold 2·5cm, intervention threshold 5·0cm.
Table 2: Mean life-years and costs for reference case and best alternative strategy from screening age until age 95 years
Figure 2: Cost-effectiveness acceptability curves of invitation to AAA 
screening from the probabilistic sensitivity analyses. 
Willingness-to-pay is the amount that a particular health provider is prepared to 
pay for each additional QALY of benefit, which for the National Institute of 
Health and Care Excellence is usually considered in the range of £20 000–30 000. 
AAA=abdominal aortic aneurysm. QALY=quality-adjusted life year. The 
probability of cost-effectiveness at £20 000 per QALY is 0·18 for the reference 
case and 0·42 for the best alternative strategy. 
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alternative screening strategy was based on screening at 
age 70 years, giving a reduction of 12% in AAA-related 
deaths at age 70–80 years and by 8% at age 70–95 years, 
reducing both the number of screening invitations needed 
to prevent one AAA-death to 1800 and the ICER to 
£23 000 but with an overdiagnosis rate of more than 50%. 
This is in stark contrast to AAA screening in men, for 
which less than 700 men need to be invited to screening to 
avoid one AAA-death,5 and for which contemporary 
modelling, on the basis of current AAA prevalence in the 
UK, estimates screening to reduce AAA-related deaths by 
18% from age 65 to 75 years and by 6% from age 65 to 
95 years with a corresponding ICER of £7400.11
Addressing sex-specific clinical issues might reduce 
the harms from screening and improve the future clinical 
benefit and cost-effectiveness estimates for women; 
these include expanding the use of EVAR in women (to 
reduce both the non-intervention rate and mortality from 
elective repair). This should be achievable given that the 
UK-wide quality improvement programme reduced 
overall elective in-hospital mortality for AAA repair from 
5·4% in 2006 to 2·9% in 2016–1731,32 and that mortality is 
even lower for elective repair of screen-detected 
aneurysms (in men).6
The best alternative strategy at age 70 years that used 
woman-specific definitions of AAA (maximum aortic 
diameter ≥2·5 cm) is likely to identify many more 
aneurysms; however, in over half of these women the 
AAA would have remained asymptomatic without 
incidental detection. The concern of overdiagnosis must 
therefore be recognised. The previous definition of AAA 
for men (a maximum aortic diameter of ≥3 cm) was 
used in most published studies of AAA prevalence in 
women,10 so that prevalence appears to be much lower 
in women than in men. This is a major driver of the 
lower cost-effectiveness in women compared with men. 
In women, the average aortic diameter is smaller than 
in men,33 providing reasonable justification for sex-
specific diagnosis thresholds, since an aneurysm could 
be defined by a more than 50% focal increase in arterial 
diameter.
Nevertheless, screening women at age 70 years, as in the 
best alternative strategy, means that many of these women 
would not require intervention during their lifetime. Still, 
after the intervention threshold is reached, elective repair 
is recommended for most women as was shown by the 
relatively low proportion of over-treatment in both the 
reference case (threshold 5·5 cm) and the best alternative 
strategy (threshold 5·0 cm). This adds to the debate about 
whether the threshold for intervention of 5·5 cm, derived 
from randomised trials in which women were under-
represented, could be lowered in women. Women have a 
four times increased risk of rupture in AAA of less than 
5·5 cm diameter for a given AAA diameter compared with 
men.19 This risk, together with inspection of the available 
data for the population distribution of aortic diameters in 
women, indicates that it would be reasonable to consider 
lower intervention thresholds in women. A lowered 
threshold would have the effect of potentially offering 
elective repair at a younger age, reducing the non-
intervention rates and operative mortality.
The possible deleterious effects of a positive AAA 
diagnosis and subsequent surveillance on quality of life 
could have a sizeable effect on the cost-effectiveness of 
screening, as shown in our sensitivity analysis. Small 
and temporary changes in utility associated with 
screening might be important, given that there are 
concerns that EuroQoL EQ-5D is not sufficiently sensitive 
to identify such effects. Furthermore, psychosocial 
consequences of AAA screening, for which the available 
quantitative studies have been deemed insufficient,34,35 
could affect health-care costs,36 and complications 
following elective repair, which could be more common 
in women than in men,37 could further reduce quality of 
life. Although the magnitude of any decrements needs 
clarification, their effect is only likely to reduce cost-
effectiveness of AAA screening.
Our model also did not consider the probably higher 
cardiovascular risk in women with AAA nor the potential 
benefits of cardiovascular risk management, given that 
women often are undertreated.38 A higher risk of other 
cardiovascular deaths in women with AAA would lower 
the cost-effectiveness of AAA screening, whereas a 
screening programme that incorporated risk manage-
ment could reduce operative mortality and cardiovascular 
risk, and thus improve cost-effectiveness. Opinion in 
our convened patient and public focus group initially 
favoured universal screening and did not favour the 
Figure 3: Tornado plot showing ICER estimates for sensitivity analyses.
Blue bars show a decrease in the ICER from the reference case (grey vertical line; £30 170), red bars show an increasing 
ICER from the reference case. Details of changes to all parameter values are given in the appendix. ICER=incremental 
cost-effectiveness ratio. AAA=abdominal aortic aneurysm. NAAASP=National Abdominal Aortic Aneurysm Screening 
Programme. NVR/HES=National Vascular Registry/Hospital Episode Statistics. QALY=quality-adjusted life year. 
*Health-related quality of life decrements for diagnosis, surgery, and non-intervention for elective surgery 
(appendix). †Used the NAAASP-based distribution but doubled and halved the AAA prevalence. ‡NAAASP-based 
AAA distribution was replaced with one based on 5140 women aged 70 years screened in Sweden, while keeping the 
prevalence of AAA constant.15 §Halved and doubled the drop-out from surveillance and incidental detection rates 
simultaneously. ¶Reduced (by 20%) and increased (by 25%) the screening, surveillance, and consultation costs. 
||Reduced (by 20%) elective surgery costs while increasing (by 25%) emergency surgery costs, and vice-versa. 
**Allowed non-intervention rate to depend on age. ††Sensitivity of operative parameters investigated by using 
systematic review data (rather than NVR/HES) to inform elective and emergency operative parameters.17,25 ‡‡Reduced 
the open repair operative mortality from 8·1% estimated from NVR/HES to 5%. §§Increased re-intervention rate after 
elective open repair and AAA mortality after emergency repair.
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screening of only high-risk subgroups. Given the 
strength of the association between smoking and AAA 
in women, there might be merit and public support 
in formally assessing the effectiveness of a screening 
programme for women who have ever smoked. 
Alternatively, for women it might be more appropriate to 
consider a combined cardiovascular disease screening 
programme.23
This project has been underpinned by the development 
and implementation of a bespoke discrete event simu-
lation model to assess AAA screening.16 This model, 
which builds on a previously developed Markov model, 
gives more flexibility to assess different screening 
options, allows heterogeneity in AAA growth rates 
between individuals, and permits parameters to depend 
on patient characteristics, such as elective operative 
mortality increasing with age and AAA diameter. Other 
strengths of this research stem from the systematic 
reviews of the recent literature to obtain best estimates 
for women-specific parameters, with individual patient 
clinical trial and registry data providing accurate 
information on post-operative outcomes for both elective 
and emergency repair.
A limitation of this research is that there were key 
quantities for which information was limited or lacking, 
especially the prevalence of AAA in women (based on 
woman-specific definition of AAA) and the effect of 
both screening and elective repair on quality of life. 
Prevalence estimates were obtained from a systematic 
review of studies from between 2000 and 2012, 
with over half of women recruited from self-purchase of 
screening, which could lead to underestimation of 
general population prevalence. A population prevalence 
at age 65 years of 0·8% (the upper limit of our sensi-
tivity analysis) would result in a more favourable cost-
effectiveness ratio. Conversely, it is possible that 
prevalence has decreased since the studies were done, 
reflecting trends in both AAA prevalence seen in 
men and smoking in women, which could lower the 
cost-effectiveness of screening. Furthermore, since 
costs were all UK-based, it is not clear how relevant 
our cost-effectiveness results are to other health-
care providers; the results on clinical benefit and harm 
are likely to be more generalisable.
In conclusion, based on current evidence and 
definitions of AAA in men, population AAA screening of 
women would yield little benefit. Other screening options 
have more favourable cost-effectiveness but could lead to 
more overdiagnosis and overtreatment. Further research 
on the population-based aortic size distribution in older 
women is needed, to provide a female-specific definition 
of AAA, together with better quantitative studies of the 
effect of screening on quality of life.
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